Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABUS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $616.24M
- P/E (TTM)
- 3.59
- EPS (TTM)
- $1.12
- Dividend yield
- None
- 52-week range
- 3.50 – 5.45
- Day range
- 3.97 – 4.09
- Volume / Avg
- 2.99M / 4.98M
- Beta
- —
- Shares outstanding
- 153.29M
52-week range
ABUS stock today
On Nov 20, ABUS ended the session at $4.02, shedding $0.05 (1.23%), versus the S&P 500's 3.70% decline. Shares are 26.2% below their 52-week high of $5.45, set on Aug 21, 2026 and 14.9% above the 52-week low of $3.50, in the middle of the past year's range. ABUS is down 16.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.7%.
Arbutus Biopharma trades at 3.6x its trailing twelve-month earnings per share of $1.12.
Summary generated from market data by MetaCap's automated system. Methodology
About Arbutus Biopharma
Company profileArbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Lindsay Androski J.D., M.B.A.
- Headquarters
- Warminster, PA
- Employees
- 19
- Website
- arbutusbio.com
Financial highlights
Full financialsIn fiscal 2025, Arbutus Biopharma generated $14.1 million in revenue, up 128.2% from fiscal 2024. Arbutus Biopharma reported a net loss of $33.5 million, compared with a loss of $69.9 million a year earlier. Operating margin was -271.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $14.08M | $6.17M | $18.14M | $39.02M | $10.99M |
| Growth | +128.21% | -65.98% | -53.51% | +255.11% | +58.92% |
| Net income | $-33.50M | $-69.92M | $-72.85M | $-69.46M | $-76.25M |
| EPS (diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$5.32+32.34%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $0.30 vs —
ABUS news
All ABUS news- Arbutus Biopharma Corporation Updates Corporate Presentation and Reports $104.6M in CashNasdaqABUS, BF.A
- Arbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7MSeeking Alpha
- Arbutus Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock RisesNasdaqMRNA, MRK, ABUS
- Arbutus Biopharma Corporation Announces FDA Lifts Clinical Hold on IND Application for AB-101Nasdaq
- Why is Arbutus Biopharma stock climbing today?Investing.com
- Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 InhibitorGlobeNewswire
- After Hours Most Active for Sep 25, 2026 : FTXN, ABUS, FTXH, CMCSA, NVDA, CSCO, JPM, BMNR, EQT, CNP, PFE, CVSNasdaqFTXN, ABUS, FTXH, CMCSA
Arbutus Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs ABUS |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs ABUS |
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs ABUS |
| SGMTSagimet Biosciences Inc. Series A | 9.08 | -5.61% | $648.02M | vs ABUS |
| ANNXAnnexon Inc. | 3.10 | -9.09% | $591.37M | vs ABUS |
| IMMXImmix Biopharma Inc. | 6.96 | -1.14% | $583.33M | vs ABUS |
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs ABUS |
| APMDApnimed Inc. | 16.09 | -6.70% | $669.84M | vs ABUS |
Indexes, lists and sector
Arbutus Biopharma stock FAQ
What is Arbutus Biopharma's stock price today?
ABUS last traded at $4.02 as of Nov 20, 4:00 PM EST, down 1.23% on the day. Prices are delayed at least 15 minutes.
Does Arbutus Biopharma pay a dividend?
No. Arbutus Biopharma does not currently pay a regular cash dividend.
What is ABUS's P/E ratio?
ABUS trades at a trailing P/E ratio of 3.59.
Who is Arbutus Biopharma's CEO?
Ms. Lindsay Androski J.D., M.B.A. is the chief executive officer of Arbutus Biopharma Corporation, which has about 19 employees.
Has ABUS ever split its stock?
Yes. The most recent ABUS stock split was a 1-for-5 split on Nov 4, 2010.
What is the ABUS 52-week high?
The 52-week high for ABUS is $5.45 and the 52-week low is $3.50. The stock is currently 26.2% below its high.